Biomarin Pharmaceutical Inc (NASDAQ: BMRN) kicked off on Tuesday, up 1.01% from the previous trading day, before settling in for the closing price of $57.41. Over the past 52 weeks, BMRN has traded in a range of $52.93-$94.85.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
While this was happening, its average annual earnings per share was recorded 57.82%. With a float of $189.06 million, this company’s outstanding shares have now reached $191.76 million.
Considering the fact that the conglomerate employs 3040 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 78.86%, operating margin of 20.51%, and the pretax margin is 22.95%.
Biomarin Pharmaceutical Inc (BMRN) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Biomarin Pharmaceutical Inc is 1.42%, while institutional ownership is 98.03%. The most recent insider transaction that took place on May 20 ’25, was worth 105,928. In this transaction GVP, Chief Accounting Officer of this company sold 1,786 shares at a rate of $59.31, taking the stock ownership to the 14,173 shares. Before that another transaction happened on May 20 ’25, when Company’s Officer proposed sale 1,786 for $59.31, making the entire transaction worth $105,928.
Biomarin Pharmaceutical Inc (BMRN) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.04 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 57.82% per share during the next fiscal year.
Biomarin Pharmaceutical Inc (NASDAQ: BMRN) Trading Performance Indicators
Take a look at Biomarin Pharmaceutical Inc’s (BMRN) current performance indicators. Last quarter, stock had a quick ratio of 3.49. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.81. Likewise, its price to free cash flow for the trailing twelve months is 17.82.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 2.69, a number that is poised to hit 0.83 in the next quarter and is forecasted to reach 4.18 in one year’s time.
Technical Analysis of Biomarin Pharmaceutical Inc (BMRN)
Compared to the last year’s volume of 1.87 million, its volume of 2.43 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 82.39%.
During the past 100 days, Biomarin Pharmaceutical Inc’s (BMRN) raw stochastic average was set at 24.59%, which indicates a significant decrease from 75.60% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.41 in the past 14 days, which was lower than the 1.87 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $58.06, while its 200-day Moving Average is $64.46. Nevertheless, the first resistance level for the watch stands at $59.18 in the near term. At $60.36, the stock is likely to face the second major resistance level. The third major resistance level sits at $61.36. If the price goes on to break the first support level at $57.00, it is likely to go to the next support level at $56.00. Should the price break the second support level, the third support level stands at $54.82.
Biomarin Pharmaceutical Inc (NASDAQ: BMRN) Key Stats
The company with the Market Capitalisation of 11.12 billion has total of 191,776K Shares Outstanding. Its annual sales at the moment are 2,854 M in contrast with the sum of 426,860 K annual income. Company’s last quarter sales were recorded 745,150 K and last quarter income was 185,690 K.
